KR20140045400A - 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 - Google Patents

비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 Download PDF

Info

Publication number
KR20140045400A
KR20140045400A KR1020137033181A KR20137033181A KR20140045400A KR 20140045400 A KR20140045400 A KR 20140045400A KR 1020137033181 A KR1020137033181 A KR 1020137033181A KR 20137033181 A KR20137033181 A KR 20137033181A KR 20140045400 A KR20140045400 A KR 20140045400A
Authority
KR
South Korea
Prior art keywords
testosterone
gel formulation
intranasal administration
gel
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137033181A
Other languages
English (en)
Korean (ko)
Inventor
웨인 크레프너
시오반 포가티
워너 오브레거
파울 조제 피에르 마리 메스
Original Assignee
트리멜 바이오파마 에스알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트리멜 바이오파마 에스알엘 filed Critical 트리멜 바이오파마 에스알엘
Publication of KR20140045400A publication Critical patent/KR20140045400A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137033181A 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 Ceased KR20140045400A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US61/486,324 2011-05-15
US201161486634P 2011-05-16 2011-05-16
US61/486,634 2011-05-16
PCT/IB2012/001112 WO2012156820A1 (en) 2011-05-15 2012-05-15 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197029484A Division KR20190117803A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도

Publications (1)

Publication Number Publication Date
KR20140045400A true KR20140045400A (ko) 2014-04-16

Family

ID=46579248

Family Applications (10)

Application Number Title Priority Date Filing Date
KR1020137033181A Ceased KR20140045400A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020237008221A Ceased KR20230041081A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020207006630A Ceased KR20200028503A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020187038088A Active KR102088038B1 (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020217007047A Active KR102568894B1 (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020137033180A Ceased KR20140033408A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020217036024A Ceased KR20210135003A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020247037387A Pending KR20240162608A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020197029484A Ceased KR20190117803A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020207028301A Ceased KR20200118228A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도

Family Applications After (9)

Application Number Title Priority Date Filing Date
KR1020237008221A Ceased KR20230041081A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020207006630A Ceased KR20200028503A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020187038088A Active KR102088038B1 (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020217007047A Active KR102568894B1 (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020137033180A Ceased KR20140033408A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
KR1020217036024A Ceased KR20210135003A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020247037387A Pending KR20240162608A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020197029484A Ceased KR20190117803A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
KR1020207028301A Ceased KR20200118228A (ko) 2011-05-15 2012-05-15 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도

Country Status (16)

Country Link
EP (3) EP3977982A1 (enExample)
JP (9) JP6152092B2 (enExample)
KR (10) KR20140045400A (enExample)
CN (4) CN109481394B (enExample)
AR (2) AR086409A1 (enExample)
AU (11) AU2012257492A1 (enExample)
BR (2) BR112013029336B1 (enExample)
CA (3) CA2836398C (enExample)
DK (1) DK2714006T3 (enExample)
EA (1) EA201391701A1 (enExample)
ES (1) ES2859784T3 (enExample)
IL (2) IL229401A0 (enExample)
MX (4) MX374398B (enExample)
PL (1) PL2714006T4 (enExample)
WO (2) WO2012156822A1 (enExample)
ZA (2) ZA201309264B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
JP6152092B2 (ja) * 2011-05-15 2017-06-28 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150297733A1 (en) * 2012-11-14 2015-10-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP4382165A3 (en) * 2013-10-07 2024-08-21 Antares Pharma, Inc. Hematocrit modulation through needle assisted jet injection of testosterone
EP4062918A1 (en) * 2014-02-19 2022-09-28 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
WO2016123317A1 (en) * 2015-01-28 2016-08-04 Prometheon Pharma, Llc Topical formulations of growth factors
EP4233873A3 (en) * 2015-06-29 2023-10-18 Lyra Therapeutics, Inc. Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
AU2017206048B2 (en) * 2016-01-07 2023-04-13 Viramal Limited Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3021989A1 (en) 2016-04-25 2017-11-02 Marc Andrew Koska Medical delivery system
CA3026274A1 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
KR102387241B1 (ko) * 2016-06-03 2022-04-15 엠 이티 피 파마 아게 다공성 부형제를 갖는 비강용 약제학적 조성물
CA3050361A1 (en) 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
WO2018231028A1 (ko) * 2017-06-17 2018-12-20 엘지전자(주) 무선 통신 시스템에서 단말의 등록 방법 및 이를 위한 장치
WO2019099954A1 (en) 2017-11-17 2019-05-23 Koska Family Limited Systems and methods for fluid delivery manifolds
CN111386119A (zh) * 2017-11-27 2020-07-07 Aska制药株式会社 粉末鼻腔给药制剂
MX2020008147A (es) 2018-02-02 2020-10-28 Acerus Biopharma Inc Metodos de terapia de testosterona.
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
SG11202106306YA (en) * 2018-12-14 2021-07-29 Acerus Biopharma Inc Active ester derivatives of testosterone, compositions and uses thereof
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
IL302986A (en) * 2020-11-19 2023-07-01 Acousia Therapeutics Gmbh A non-aqueous gel preparation
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
KR100648536B1 (ko) * 1997-11-10 2006-11-24 셀러지 파마세우티칼스, 인크 침투 보강 및 자극 감소를 위한 계
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
MXPA04003359A (es) * 2001-10-12 2004-11-29 Cns Corporated Gel nasal hidratante y dispositivo aplicador.
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
PL1670433T3 (pl) * 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
AU2005313601B2 (en) * 2004-12-09 2012-05-24 Bayer Intellectual Property Gmbh Stabilisation of glucocorticoid esters with acids
CA2610708C (en) * 2005-06-03 2013-10-08 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
RU2480208C2 (ru) * 2006-10-04 2013-04-27 М Унд П Патент Акциенгезелльшафт Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
AU2008231781B2 (en) * 2007-03-23 2012-09-20 Besins Healthcare Luxembourg Sarl Compositions and method for treating pediatric hypogonadism
EP2191833B1 (en) * 2007-09-20 2013-02-13 Shiseido Company, Ltd. Transdermally absorbable preparation
EP2060300B1 (en) * 2007-11-13 2015-04-15 Curadis GmbH C-19 steroids for therapeutic uses
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
JP6152092B2 (ja) * 2011-05-15 2017-06-28 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム

Also Published As

Publication number Publication date
MX363561B (es) 2019-03-27
AU2022202402A1 (en) 2022-05-12
JP2021001206A (ja) 2021-01-07
MX2020008599A (es) 2022-08-31
MX395212B (es) 2025-03-21
KR20200118228A (ko) 2020-10-14
AU2024216312A1 (en) 2024-10-24
ES2859784T3 (es) 2021-10-04
KR20200028503A (ko) 2020-03-16
AU2020210227A1 (en) 2020-08-20
JP2022078222A (ja) 2022-05-24
ZA201309265B (en) 2016-01-27
EP2709588B1 (en) 2021-08-25
PL2714006T3 (pl) 2021-08-16
CA3034552C (en) 2023-02-07
AU2019203400A1 (en) 2019-08-01
CA2836398C (en) 2021-12-14
KR102568894B1 (ko) 2023-08-21
ZA201309264B (en) 2015-09-30
KR20210135003A (ko) 2021-11-11
JP2022105175A (ja) 2022-07-12
AU2020267162B2 (en) 2022-06-09
AR089553A1 (es) 2014-09-03
EP2714006A1 (en) 2014-04-09
AR086409A1 (es) 2013-12-11
JP6594924B2 (ja) 2019-10-23
KR20140033408A (ko) 2014-03-18
AU2019201618A1 (en) 2019-04-18
WO2012156820A9 (en) 2014-02-20
JP2014515038A (ja) 2014-06-26
EP2709588A1 (en) 2014-03-26
CA2836405A1 (en) 2012-11-22
CN103796636B (zh) 2019-04-05
KR20190006194A (ko) 2019-01-17
JP2020073469A (ja) 2020-05-14
JP6152092B2 (ja) 2017-06-28
BR112013029336B1 (pt) 2021-11-30
CN109481394A (zh) 2019-03-19
PL2714006T4 (pl) 2021-08-16
AU2012257492A1 (en) 2013-12-19
MX374398B (es) 2025-03-06
KR102088038B1 (ko) 2020-03-13
JP2020079257A (ja) 2020-05-28
BR112013029332A2 (pt) 2021-06-01
AU2017203470A1 (en) 2017-06-22
AU2020267162A1 (en) 2020-12-03
KR20240162608A (ko) 2024-11-15
KR20210029849A (ko) 2021-03-16
AU2017204182A1 (en) 2017-07-20
BR112013029336A2 (pt) 2020-08-11
CN103813784A (zh) 2014-05-21
AU2019203067A1 (en) 2019-05-23
IL229401A0 (en) 2014-01-30
MX2013013388A (es) 2014-09-15
EP3977982A1 (en) 2022-04-06
MX2013013369A (es) 2014-10-17
WO2012156822A1 (en) 2012-11-22
AU2012257490A1 (en) 2013-12-19
CA3034552A1 (en) 2012-11-22
JP7017254B2 (ja) 2022-02-08
KR20230041081A (ko) 2023-03-23
JP2017160204A (ja) 2017-09-14
MX2019003340A (es) 2019-07-04
WO2012156820A1 (en) 2012-11-22
CN109481394B (zh) 2023-05-05
KR20190117803A (ko) 2019-10-16
JP2018199701A (ja) 2018-12-20
CN103796636A (zh) 2014-05-14
IL229400A0 (en) 2014-01-30
CN110613679A (zh) 2019-12-27
JP2014513716A (ja) 2014-06-05
EP2714006B1 (en) 2020-12-09
CA2836398A1 (en) 2012-11-22
DK2714006T3 (da) 2021-03-15
CA2836405C (en) 2021-09-07
EA201391701A1 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
AU2024216312A1 (en) Intranasal testosterone gel formulations and use thereof for treating male hypogonadism
US20250064831A1 (en) Controlled release topical testosterone formulations and methods
US20250009756A1 (en) Male Testosterone Titration Methods, Male Intranasal Testosterone Bio-Adhesive Gel Formulations and Use Thereof for Treating Hypogonadism and TRT
US20240316063A1 (en) Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
HK1263036A1 (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1263036B (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1196287A (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1196287B (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
EA039080B1 (ru) Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
HK1196261B (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131213

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160106

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170515

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180517

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190327

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180517

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190327

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181119

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190705

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190327

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181119

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180517

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191007